The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

Optibiotix Health plc Signs 5 year Exclusive Agreement with Trigen Pharma
Pharma & Human Health

Optibiotix Health plc Signs 5 year Exclusive Agreement with Trigen Pharma

APR 18, 2018
Landmark Study To Address Global Malnutrition And Restorative Effect Of Infant Probiotic
Biotics and Supplements

Landmark Study To Address Global Malnutrition And Restorative Effect Of Infant Probiotic

APR 17, 2018
Inocucor Acquires Leading Crop Nutrition Company, Plans New Class of High-Performance Crop Inputs
Finance

Inocucor Acquires Leading Crop Nutrition Company, Plans New Class of High-Performance Crop Inputs

APR 17, 2018
WACKER Strengthens Its Pharmaceutical-Protein Business and Buys SynCo Bio Partners
Finance

WACKER Strengthens Its Pharmaceutical-Protein Business and Buys SynCo Bio Partners

APR 17, 2018
MicroBiome Therapeutics Launches Clinically-Tested Dietary Supplement Engineered to Modulate the Gut Microbiome
Biotics and Supplements

MicroBiome Therapeutics Launches Clinically-Tested Dietary Supplement Engineered to Modulate the Gut Microbiome

APR 11, 2018
Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
Clinical & Manufacturing

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

APR 9, 2018
Synlogic Announces Registered Direct Offering of Common Stock
Biotics and Supplements

Synlogic Announces Registered Direct Offering of Common Stock

APR 6, 2018
Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)
Finance

Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)

APR 5, 2018
Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.
Finance

Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.

APR 5, 2018
Symbiotix Biotherapies Announces License Agreement with Harvard University
Pharma & Human Health

Symbiotix Biotherapies Announces License Agreement with Harvard University

MAR 21, 2018
AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery
Clinical & Manufacturing

AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery

MAR 21, 2018